CD38 as a prognostic marker in CLL
- PMID: 16019444
- DOI: 10.1080/10245330400020470
CD38 as a prognostic marker in CLL
Abstract
Cell-surface expression of CD38 in CLL has been recognised recently as a marker of progressive disease and poor outcome. In contrast to traditional staging systems, CD38 is able to identify progressive cases at an early stage. Measurement of CD38, in conjunction with other novel prognostic factors such as p53 and ZAP-70 helps to identify patients who might benefit from early and more intensive therapy. In addition, CD38 positivity can predict unmutated IgVH gene mutation status in most cases. These features, together with its easy applicability, render CD38 a valuable tool in the routine diagnostics of CLL. Questions remaining to be clarified about CD38 include the incidence and significance of its variations during the course of the disease, the optimal method to define CD38 positivity and the impact of different methodologies on results. Only after these issues are resolved can the definitive place of CD38 be defined in the diagnostics of CLL.
Similar articles
-
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.Blood. 2003 Jun 15;101(12):4944-51. doi: 10.1182/blood-2002-10-3306. Epub 2003 Feb 20. Blood. 2003. PMID: 12595313
-
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.Leukemia. 2005 May;19(5):750-8. doi: 10.1038/sj.leu.2403707. Leukemia. 2005. PMID: 15759031
-
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.N Engl J Med. 2003 May 1;348(18):1764-75. doi: 10.1056/NEJMoa023143. N Engl J Med. 2003. PMID: 12724482
-
The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL).Leuk Lymphoma. 2004 Mar;45(3):455-62. doi: 10.1080/1042819032000141275. Leuk Lymphoma. 2004. PMID: 15160906 Review.
-
The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia.J Biol Regul Homeost Agents. 2004 Jul-Dec;18(3-4):340-6. J Biol Regul Homeost Agents. 2004. PMID: 15786702 Review.
Cited by
-
Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia.Pathol Oncol Res. 2005;11(4):205-10. doi: 10.1007/BF02893852. Epub 2005 Dec 31. Pathol Oncol Res. 2005. PMID: 16388316 Review.
-
Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.Cancer Immunol Immunother. 2007 Apr;56(4):501-14. doi: 10.1007/s00262-006-0207-x. Epub 2006 Oct 19. Cancer Immunol Immunother. 2007. PMID: 17051411 Free PMC article.
-
CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint.Front Oncol. 2021 Jun 15;11:687430. doi: 10.3389/fonc.2021.687430. eCollection 2021. Front Oncol. 2021. PMID: 34211854 Free PMC article.
-
IFN-γ and CD38 in Hyperprogressive Cancer Development.Cancers (Basel). 2021 Jan 15;13(2):309. doi: 10.3390/cancers13020309. Cancers (Basel). 2021. PMID: 33467713 Free PMC article. Review.
-
A Cross Sectional Study on T Cells and Subsets in Chronic Lymphocytic Leukemia and their Association with Clinical Phenotype.Indian J Hematol Blood Transfus. 2021 Oct;37(4):563-568. doi: 10.1007/s12288-021-01397-x. Epub 2021 Jan 21. Indian J Hematol Blood Transfus. 2021. PMID: 34744340 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
